Hedgehog Signaling Pathway Mediates Gemcitabine Intrinsic Chemoresistance in Pancreatic Cancer

Xinyu SHAO,Shen GU,Xiwei DING,Xiaoping ZOU

DOI: https://doi.org/10.3969/j.issn.1008-7125.2016.11.004

2016-01-01

Abstract:Background:Gemcitabine is the standard first-line chemotherapy for pancreatic cancer. However,chemoresistance commonly occurs and is the main cause of therapeutic failure. Hedgehog (Hh)pathway is a core signaling pathway in the initiation and progression of pancreatic cancer,the aberrant activation of Hh pathway is associated with the expression of multidrug resistance related proteins and the maintenance and self-renewal of cancer stem cells. Aims:To investigate the correlation between expressions of Hh pathway related factors and gemcitabine intrinsic chemoresistance in pancreatic cancer. Methods:Human pancreatic cancer cell line CFPAC-1 and PANC-1 were treated with gemcitabine,GANT61 --the inhibitor of Hh pathway,purmorphamine -- the agonist of Hh pathway,and gemcitabine combined with GANT61 or purmorphamine,respectively. Expressions of the Hh pathway related factors Shh,Ptch,Smo and Gli1 were detected by real-time PCR and Western blotting,and CCK-8 assay was used to assess the effect of various interventions on cell viability. Results:Compared with CFPAC-1 cells,expressions of Hh pathway related factors were significantly higher in PANC-1 cells (P <0. 05 )and PANC-1 cells was more resistant to gemcitabine. GANT61 could down-regulate Gli1 expression and increase the sensitivity to gemcitabine in PANC-1 cells,whereas purmorphamine could up-regulate the expression of Glil and decrease the sensitivity to gemcitabine in CFPAC-1 cells (P all <0. 05). Conclusions:Expressions of Hh pathway related factors are correlated with gemcitabine intrinsic chemoresistance in pancreatic cancer. Inhibiting Hh pathway aberrant activation might increase the sensitivity of pancreatic cancer cells to gemcitabine.